

## DAFTAR PUSTAKA

- Abdulmir, A., Hafidh, R., Abdulmuhammen, N., Abubakar, F., & Abbas, K., 2008. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. *BMC Public Health*, 8(1). <https://doi.org/10.1186/1471-2458-8-400>
- Adham, M., Kurniawan, A. N., Muhtadi, A. I., Roezin, A., Hermani, B., Gondhowiardjo, S., Tan I. B., Middeldorp, J. M., 2012. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. *Chinese Journal of Cancer*, 31(4), 185–196. <https://doi.org/10.5732/cjc.011.10328>
- Adham, M., Rohdiana, D., Mayangsari, I. D., and Musa, Z., 2014. Delayed diagnosis of nasopharyngeal carcinoma in a patient with early signs of unilateral ear disorder. *Medical Journal of Indonesia*, 52. <https://doi.org/10.13181/mji.v23i1.689>
- Altman, D. G., Bland, J. B., 1994. Diagnostic tests 1: sensitivity and specificity. *BMJ* 1994;308:1552
- Amene, C., Cosetti, M., Ambekar, S., Guthikonda, B., & Nanda, A., 2013. Johann Christian Rosenmüller (1771-1820): A Historical Perspective on the Man behind the Fossa. *Journal of Neurological Surgery Part B: Skull Base*, 74(04), 187–193. <https://doi.org/10.1055/s-0033-1342927>
- Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., Winchester, D. P., 2017. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA: A Cancer Journal for Clinicians*, 67(2), 93–99. <https://doi.org/10.3322/caac.21388>
- Amon, W., Binne, U. K., Bryant, H., Jenkins, P. J., Karstegl, C. E., and Farrell, P. J., 2004. Lytic Cycle Gene Regulation of Epstein-Barr Virus. *Journal of Virology*, 78(24), 13460-13469. <https://dx.doi.org/10.1128/JVI.78.24.13460-13469.2004>
- Anita, K. W., Putranto, B. E., Paramita, D. K., 2015. Ekspresi EBER pada Berbagai Tipe Histopatologi Karsinoma Nasofaring. *Majalah Patologi* Vol.24 No. 1, p. 7-11.
- Aoki, V., Sousa Jr, J. X., Fukumori, L. M. I., Périgo, A. M., Freitas, E. L., and Oliveira, Z. N. P., 2010. Direct and Indirect Immunofluorescence. *Anais*

Brasileiros de Dermatologia, 85(4), 490–500. <http://dx.doi.org/10.1590/S0365-05962010000400010>

Bahadır, E. B., & Sezgintürk, M. K. (2016). Lateral flow assays: Principles, designs and labels. *TrAC Trends in Analytical Chemistry*, 82, 286–306. <https://doi.org/10.1016/j.trac.2016.06.006>

Banko, A. V., Lazarevic, I. B., Karalic, D. Z., Djukic, V. B., Cupic, M. D., Stevanovic, G., and Jovanovic, T. P., 2018. The sequence analysis of Epstein–Barr virus EBNA1 gene: could viral screening markers for nasopharyngeal carcinoma be identified? *Medical Microbiology and Immunology*. <https://doi.org/10.1007/s00430-018-0561-2>

Blanchard, P., Lee, A., Marguet, S., Leclercq J., Ng, W. T., Ma, J., Chan, A. T., Huang P. Y., Benhamou, E., Zhu, G., Chua, D/ T., Chen, Y., Mai, H. Q., Kwong, D. L., Cheah, S. L., Moon, J., Tung, Y., Chi, K. H., Fountzilias, G., Zhang, L., Hui, E. P., Lu, T. X., Bourhis, J., Pignon, J. P., MAC-NPC Collaborative Group. 2015. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *Lancet Oncol.* 2015 Jun;16(6):645-55. [https://doi.org/10.1016/S1470-2045\(15\)70126-9](https://doi.org/10.1016/S1470-2045(15)70126-9)

Brennan, B., 2006. *Orphanet Journal of Rare Diseases*, 1(1), 23. <https://dx.doi.org/10.1186%2F1750-1172-1-23>

Cao, Y., 2017. EBV based cancer prevention and therapy in nasopharyngeal carcinoma. *Npj Precision Oncology*, 1(1). <https://dx.doi.org/10.1038%2Fs41698-017-0018-x>

Cao, S. M., Simons, M. J., and Qian, C.N., 2011. The prevalence and prevention of nasopharyngeal carcinoma in China. *Chinese Journal of Cancer*, 30(2), 114–119. <https://dx.doi.org/10.5732%2Fjc.010.10377>

Cen, O., and Longnecker, R., 2015. Latent Membrane Protein 2 (LMP2). *Current Topics in Microbiology and Immunology*, 151–180. [https://doi.org/10.1007/978-3-319-22834-1\\_5](https://doi.org/10.1007/978-3-319-22834-1_5)

Chan, K. C. A., Hung, E. C. W., Woo, J. K. S., Chan, P. K. S., Leung, S.-F., Lai, F. P. T., Cheng, A. S. M., Yeung, S. W., Chan, T. W., Tsui, T. K. C., Kwok, J. S. S., King, A. D., Chan, A. T. C., Hasselt, A. C. V., and Lo, Y. M. D. (2013). Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. *Cancer*, 119(10), 1838–1844. <https://doi.org/10.1002/cncr.28001>

- Cheesman, K., & Burdett, E., 2011. Anatomy of the nose and pharynx. *Anaesthesia & Intensive Care Medicine*, 12(7), 283–286. <https://doi.org/10.1016/j.mpaic.2011.04.013>
- Chen, C. J., Hsu, W. L., Yang, H. I., Lee, M. H., Chen, H. C., Chien, Y. C., and You, S. L., 2013. Epidemiology of Virus Infection and Human Cancer. *Recent Results in Cancer Research*, 11–32. [https://doi.org/10.1007/978-3-642-38965-8\\_2](https://doi.org/10.1007/978-3-642-38965-8_2)
- Chen, L., Hu, C.-S., Chen, X.-Z., Hu, G.-Q., Cheng, Z.-B., Sun, Y., Li, W. X., Chen, Y. Y., Xie, F. Y., Liang, S. B., Chen, Y., Xu, T. T., Li, B., Long, G. X., Wang, S. Y., Zheng, B. M., Guo, Y., Sun, Y., Mao, Y. P., Tang, L. L., Chen, Y. M., Liu, M. Z., and Ma, J., 2017. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. *European Journal of Cancer*, 75, 150–158. <https://doi.org/10.1016/j.ejca.2017.01.002>
- Chen, W. S., Li, J. J., Hong, L., Xing, Z. B., Wang, F., and Li, C. Q., 2016. Comparison of MRI, CT and 18F-FDG PET/CT in the diagnosis of local and metastatic of nasopharyngeal carcinomas: an updated meta analysis of clinical studies. *American journal of translational research*, 8(11), 4532–4547.
- Chen, M., Yin, L., Wu, J., Gu, J. J., Jiang, X. S., Wang, D. J., Zong, D., Guo, C., Zhu, H. F., Wu, J. F., He, X., Guo, W. J., 2015. Impact of Plasma Epstein-Barr Virus-DNA and Tumor Volume on Prognosis of Locally Advanced Nasopharyngeal Carcinoma. *BioMed Research International*, 2015, 1–5. <https://dx.doi.org/10.1155%2F2015%2F617949>
- Chesnokova, L. S., Valencia, S. M., and Hutt-Fletcher, L. M., 2016. The BDLF3 gene product of Epstein-Barr virus , gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection. *Virology*, 494, 23–28. <https://dx.doi.org/10.1016%2Fj.virol.2016.04.002>
- Coghill, A. E., Hsu, W. L., Pfeiffer, R. M., Juwana, H., Yu, K. J., Lou, P. J., Wang, C. P., Chen, J. Y., Chen, C. J., Middeldorp, J. M., Hildesheim, A., 2014. Epstein–Barr Virus Serology as a Potential Screening Marker for Nasopharyngeal Carcinoma among High-Risk Individuals from Multiplex Families in Taiwan. *Cancer Epidemiol Biomarkers Prev*; 23(7) July 2014. <https://dx.doi.org/10.1158/1055-9965.EPI-13-1262>
- Copple, S. S., Sawitzke, A. D., Wilson, A. M., Tebo, A. E., and Hill, H. R., 2011. Enzyme-Linked Immunosorbent Assay Screening Then Indirect Immunofluorescence Confirmation of Antinuclear Antibodies. *American*

Journal of Clinical Pathology, 135(5), 678–684.  
<https://doi.org/10.1309/ajcp6r8eelgodayw>

Craven, J. (2005). Anatomy of the naso- and oropharynx. *Anaesthesia & Intensive Care Medicine*, 6(7), 217–218. <https://doi.org/10.1383/anes.2005.6.7.217>

Crowley, A., Connell, J., Schaffer, K., Hall, W., and Hassan, J., 2012. Is There Diagnostic Value in Detection of Immunoglobulin G Antibodies to the Epstein–Barr Virus Early Antigen? *BioResearch Open Access*, 1(6), 291–296. <https://dx.doi.org/10.1089%2Fbiores.2012.0274>

Dadari, R., Hinderer, W., Land, D., Benider, A., Gueddari, B. E., Joab, I., Benslimane, A., and Khyatti, M., 2001. Antibody Responses to Recombinant Epstein-Barr Virus Antigens in Nasopharyngeal Carcinoma Patients: Complementary Test of ZEBRA Protein and Early Antigens p54 and p138. *JOURNAL OF CLINICAL MICROBIOLOGY*, Sept. 2001, p. 3164–3170 Vol. 39, No. 9 <https://doi.org/10.1128/JCM.39.9.3164-3170.2001>

Dandona, M. A., Morgensztern, D., Auethavekiat, V., Adkins, D., Thorstad, W., Nussenbaum, B., Zhang, Q., and Kuperman, D. I. Survival for nasopharyngeal cancer with distant metastatic disease at presentation. *Journal of Clinical Oncology* 2009 27:15S, e17004-e17004. <https://doi.org/10.1200/jco.2009.27.15s.e17004>

Despachale, M. D., Clerici, P., 2012. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. *World J Virol* 2012 February 12; 1(1): 31-43. <https://doi.org/10.5501/wjv.v1.i1.31>

Donaldson, J. G., 2015. Immunofluorescence Staining. *Current Protocols in Cell Biology*, 4.3.1–4.3.7. <https://doi.org/10.1002/0471143030.cb0403s69>

Dou H. Q., Hu D. Y., Lam C. L., Liu Y. S., Wang X. W., and Zhang W. D., 2014. Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Macao. *Chin J Cancer Res*. 2014 Apr; 26(2): 148–158. <https://dx.doi.org/10.3978%2Fj.issn.1000-9604.2014.03.01>

Draborg, A. H., Duus, K., and Houen, G., 2012. Epstein-Barr Virus and Systemic Lupus Erythematosus. *Clinical and Developmental Immunology*, 2012, 1–10. <https://dx.doi.org/10.1155%2F2012%2F370516>

Drake, R. L., Vogl, W., Mitchell, A. W. M., 2009. *Gray's Anatomy for Students* 2nd International Edition. Elsevier. ISBN 9780323286022

Erickson, K. D., and Martin, J. M., 1997. Early Detection of the Lytic LMP-1 Protein in EBV-Infected B-Cells Suggests Its Presence in the Virion. *Virology*, 234(1), 1–13. <http://dx.doi.org/10.1006/viro.1997.8638>

- Fachiroh, J., Paramita, D. K., Hariwiyanto, B., Harijadi, A., Dahlia, H. L., Indrasari, S. R., Kusumo, H., Zeng, Y. S., Schouten, T., Mubarika, S., Middeldorp, J. M., 2005. Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field Screening. *JOURNAL OF CLINICAL MICROBIOLOGY*, Apr. 2006, p. 1459-1467. <https://doi.org/10.1128/JCM.44.4.1459-1467.2006>
- Fachiroh, J., Prasetyanti, P. R., Paramita, D. K., Prasetyawati, A. T., Anggrahini, D. W., Haryana, S. M., & Middeldorp, J. M., 2008. *Dried-Blood Sampling for Epstein-Barr Virus Immunoglobulin G (IgG) and IgA Serology in Nasopharyngeal Carcinoma Screening. Journal of Clinical Microbiology*, 46(4), 1374–1380. doi:10.1128/jcm.01368-07
- Fachiroh, J., Stevens, S. J. C., Haryana, S. M., and Middeldorp, J. M., 2010. Combination of Epstein–Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease. *Journal of Virological Methods*, 169(1), 79–86. <https://doi.org/10.1016/j.jviromet.2010.07.001>
- Fachiroh, J., Schouten, T., Hariwiyanto, B., Paramita, D. K., Harijadi, A., Haryana, S. M., Middeldorp, J. M., 2004. Molecular Diversity of Epstein- Barr Virus IgG and IgA Antibody Responses in Nasopharyngeal Carcinoma: A Comparison of Indonesian, Chinese, and European Subjects. *The Journal of Infectious Diseases*, 190(1), 53–62. <https://doi.org/10.1086/421245>
- Frappier, L., 2015. EBNA1. *Current Topics in Microbiology and Immunology*, 3–34. [https://doi.org/10.1007/978-3-319-22834-1\\_1](https://doi.org/10.1007/978-3-319-22834-1_1)
- Gao, R., Wang, L., Liu, Q., Zhang, L. F., Ye, Y. F., Xie, S. H., Du, J. L., Chen, S. H., Guo, J., Yang, M. J., Lin, C. H., Cao, S. M., Evaluation of seven recombinant VCAIgA ELISA kits for the diagnosis of nasopharyngeal carcinoma in China: a case–control trial. *BMJ Open* 2017;7:e013211. <https://doi.org/10.1136/bmjopen-2016-013211>
- Gärtner, B. C., Hess, R. D., Bandt, D., Kruse, A., Rethwilm, A., Roemer, K., and Mueller-Lantsch, N., 2003. Evaluation of Four Commercially Available Epstein-Barr Virus Enzyme Immunoassays with an Immunofluorescence Assay as the Reference Method. *CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY*, Jan. 2003, p. 78–82 Vol. 10, No. 1. <https://doi.org/10.1128/CDLI.10.1.78–82.2003>

- Gilbert, R., Logan, S., Moyer, V. A., Elliot, E. J., 2001. Assessing Diagnostic and Screening Test: Part 1. Concepts. WJM Volume 174 June 2001
- Görg, C., Kunsch, S., and Neesse, A., 2014. [Incidental findings in abdominal ultrasound. Characteristics and clinical interpretation]. *Der Internist*, 55(9), 998–1018. <https://doi.org/10.1007/s00108-014-3454-5>
- Goudarzi, S., Ahmadi, A., Farhadi, M., Kamrava, S. K., Saghafi, S., Omidfar, K., 2015. Development of a New Immunochromatographic Assay Using Gold Nanoparticles for screening of IgA Deficiency. *Iran J Allergy Asthma Immunol* February 2015; 14(1):105-112
- Gnoth, C., and Johnson, S., 2014. Strips of Hope: Accuracy of Home Pregnancy Tests and New Developments. *Geburtsh Frauenheilk* 2014; 74:661–669. <http://dx.doi.org/10.1055/s-0034-1368589>
- Grunsven, W. M. V., Spaan, W. J., Middeldorp, J. M., 1994. Localization and Diagnostic Application of Immunodominant Domains of the BFRF3-encoded Epstein-Barr Virus Capsid Protein. *National Center for Biotechnology Information*
- Gulley, M. L., and Tang, W., 2008. Laboratory Assays for Epstein-Barr Virus-Related Disease. *The Journal of Molecular Diagnostics*, 10(4), 279–292. <https://doi.org/10.2353/jmoldx.2008.080023>
- Guo, X., Johnson, R. C., Deng, H., Liao, J., Guan, L., Nelson, G. W., Tang, M. Z., Zheng, Y. M., The, G. D., O'Brien, S. J., Winkler, C. A., Zeng, Y., 2009. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. *International Journal of Cancer*, 124(12), 2942–2947. <https://doi.org/10.1002/ijc.24293>
- Hørding, U., Nielsen, H. W., Albeck, H., Daugaard, S., 1993. Nasopharyngeal carcinoma: histopathological types and association with Epstein-Barr Virus. *Eur J Cancer B Oral Oncol*. 1993 Apr;29B(2):137-9
- Hatton, O. L., Harris-Arnold, A., Schaffert, S., Krams, S. M., & Martinez, O. M., 2014. The interplay between Epstein–Barr virus and B lymphocytes: implications for infection, immunity, and disease. *Immunologic Research*, 58(2-3), 268–276. <https://dx.doi.org/10.1007%2Fs12026-014-8496-1>
- Herman, C., 2006. What makes a Screening Exam “ Good”? *Virtual Mentor*, January, 2006—Vol 8, No 1: 34-37
- Ho, C. S., 2017. Beating ‘Guangdong cancer’: a review and update on nasopharyngeal cancer. *Hong Kong Med J* Volume 23 Number 5 October 2017.

- Hu, J., Kong, L., Gao, J., Hu, W., Guan, X., and Lu, J. J., 2017. Use of Radiation Therapy in Metastatic Nasopharyngeal Cancer Improves Survival: A SEER Analysis. *Scientific Reports*, 7(1). <https://doi.org/10.1038/s41598-017-00655-1>
- Hutajulu, S. H., Fachiroh, J., Argy, G., Indrasari, S. R., Indrawati, L. P. L., Paramita, D. K., Jati T. B. R., Middeldorp, J. M., 2017. Seroprevalence of IgA anti Epstein-Barr virus is high among family members of nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and neck area. *PLOS ONE*, 12(8), e0180683. <https://doi.org/10.1371/journal.pone.0180683>
- Hutt-Fletcher, L. M., 2014. Epstein–Barr virus replicating in epithelial cells. *Proceedings of the National Academy of Sciences*, 111(46), 16242–16243. <https://doi.org/10.1073/pnas.1418974111>
- IARC (International Agency of Research on Cancer), 2009. *Biological Agent Volume 100B: A Review of Human Carcinogens*. WHO ISBN 978 92 832 1319 2
- Jensen, E. C., 2012. The Basics of Western Blotting. *The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology*, 295(3), 369–371. [doi:10.1002/ar.22424](https://doi.org/10.1002/ar.22424)
- Ji, M. F., Wang, D. K., Yu, Y. L., Guo, Y. Q., Liang, J. S., Cheng, W. M., Zong, Y. S., Chan, K. H., Ng, S. P., Wei, W. I., Chua, D. T. T., Sham, J. S. T., Ng, M. H., 2007. Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. *British Journal of Cancer* (2007) 96, pp. 623 – 630. <https://doi.org/10.1038/sj.bjc.6603609>
- Jia, W. H., Luo, X. Y., Feng, B. J., Ruan, H. L., Bei, J. X., Liu, W. S., Qin, H. D., Feng, Q. S., Chen, L. Z., Yao, S. Y., Zeng, Y. X., 2010. Traditional Cantonese diet and nasopharyngeal carcinoma risk: a large-scale case-control study in Guangdong, China. *BMC Cancer*, 10(1). <https://doi.org/10.1186/1471-2407-10-446>
- Jia, W. H., and Qin, H. D., 2012. Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic review. *Seminars in Cancer Biology* 22 (2012) 117– 126.
- Karray, H., Ayadi, W., Fki, L., Hammami, A., Daoud, J., Drira, M. M., Frikha, M., Jlidi, R., Middeldorp, J. M., 2005. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. *Journal of Medical Virology*, 75(4), 593–602. <https://doi.org/10.1002/jmv.20310>

- Kieser, A., and Sterz, K. R., 2015. The Latent Membrane Protein 1 (LMP1). *Current Topics in Microbiology and Immunology*, 119–149. [https://doi.org/10.1007/978-3-319-22834-1\\_4](https://doi.org/10.1007/978-3-319-22834-1_4)
- King, A. D., Vlantis, A. C., Bhatia, K. S. S., Zee, B. C. Y., Woo, J. K. S., Tse, G. M. K., Chan, A. T. C., Ahuja, A. T., 2011. Primary Nasopharyngeal Carcinoma: Diagnostic Accuracy of MR Imaging versus that of Endoscopy and Endoscopic Biopsy. *Radiology*, 258(2), 531–537. <https://doi.org/10.1148/radiol.10101241>
- Klutts, J. S., Ford, B. A., Perez, N. R., and Gronowski, A. M., 2009. Evidence-Based Approach for Interpretation of Epstein-Barr Virus Serological Patterns. *Journal of Clinical Microbiology*, 47(10), 3204–3210. <https://doi.org/10.1128/JCM.00164-09>
- Koczula, K. M., and Gallotta, A., 2016. Lateral flow assays. *Essays In Biochemistry*, 60(1), 111–120. <https://doi.org/10.1042/EBC20150012>
- Kumar, V., Abbas, A. K., Aster, J. C., 2013. *Robbins Basic Pathology Ninth Edition*. Philadelphia: Elsevier
- Kutok, J. L., and Wang, F., 2006. SPECTRUM OF EPSTEIN-BARR VIRUS–ASSOCIATED DISEASES. *Annual Review of Pathology: Mechanisms of Disease*, 1(1), 375–404. <https://doi.org/10.1146/annurev.pathol.1.110304.100209>
- Kwiecien, R., Kopp-Schneider, A., Blettner, M., 2011. Review Article Concordance Analysis Part 16 of a Series on Evaluation of Scientific Publication. *Dtsch Arztebl Int* 2011; 108(30): 515–21. <https://doi.org/10.3238/arztebl.2011.0515>
- Lassoued, S., Gargouri, B., Feki, A. E. F. E., Attia, H., Pelt, J. V., 2009. Transcription of the Epstein–Barr Virus Lytic Cycle Activator BZLF-1 During Oxidative Stress Induction. *Biol Trace Elem Res* (2010) 137:13–22 <https://doi.org/10.1007/s12011-009-8555-y>
- Leung, S. F., 2004. Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein-Barr Virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA Antibody. *Clinical Chemistry*, 50(2), 339–345. <https://doi.org/10.1373/clinchem.2003.022426>
- Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P. M., Klein, G., Kurilla, M. G., Masucci, M. G., 1995. Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. *Nature*, 375(6533), 685–688. <https://doi.org/10.1038/375685a0>

- Liang H., Xia W. X., Xing Lv, Sun R., Zeng Q., Li S. W., Mo H. Y., Han F., Luo D. H., Ye Y. F., Yang J., Ke L. R., Guo L., Chen M. Y., Cao K. J., Zhao C., Mai H. Q., Qian C. N., Guo X., Qun X. Y., 2017. Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979). *Journal of Clinical Oncology* 35, no. 15\_suppl (May 20 2017) 6006-6006. [https://doi.org/10.1200/JCO.2017.35.15\\_suppl.6006](https://doi.org/10.1200/JCO.2017.35.15_suppl.6006)
- Lin, J. C., Wang, W. Y., Chen, K. Y., Wei, Y. H., Liang, W. M., Jan, J. S., and Jiang, R. S., 2004. Quantification of Plasma Epstein–Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma. *New England Journal of Medicine*, 350(24), 2461–2470. <https://doi.org/10.1056/NEJMoa032260>
- Lindsey, J. W., and Hatfield, L. M., 2010. Epstein-Barr virus and multiple sclerosis: Cellular immune response and cross-reactivity. *Journal of Neuroimmunology*, 229(1-2), 238–242. <http://dx.doi.org/10.1016/j.jneuroim.2010.08.009>
- Liu, Z. W., Ji, M. F., Huang, Q. H., Fang, F., Liu, Q., Jia, W. H., Guo, X., Xie, S. H., Chen, F., Liu, Y., Mo, H. Y., Liu, W. L., Yu, Y. L., Cheng, W. M., Yang, Y. Y., Wu, B. H., Wei, K. R., Ling, W., Lin, X., Lin, E. H., Ye, W. M., Hong, M. H., Zeng, Y. X., Cao, S. M., 2013. Two Epstein-Barr Virus–Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern China. *American Journal of Epidemiology* Vol. 177, No.3; pp. 242- 250. <https://doi.org/10.1093/aje/kws404>
- Liu, Z., Ye, W., Zeng, Y. X., and Cao, S. M., 2012. Liu et al. Respond to “Epstein-Barr Virus Screening for Nasopharyngeal Carcinoma.” *American Journal of Epidemiology*, 177(3), 254–255. <https://doi.org/10.1093/aje/kws405>
- Loh, K. S., Goh, B. C., Lu, J., Hsieh, W. S., and Tan, L., 2006. Familial Nasopharyngeal Carcinoma in a Cohort of 200 Patients. *Archives of Otolaryngology–Head & Neck Surgery*, 132(1), 82. <https://doi.org/10.1001/archotol.132.1.82>
- Mannan, R., 2014. Nasal cavity, paranasal sinuses, nasopharynx section Nasopharyngeal Carcinoma : Keratinizing squamous cell carcinoma, non-keratinizing squamous cell carcinoma and undifferentiated nasopharyngeal carcinoma. <http://www.pathologyoutlines.com/topic/nasalkeratinizing.html> and <http://www.pathologyoutlines.com/topic/nasalnonkeratinizingundiff.html>.
- Merchant, M., Caldwell, R. G., and Longnecker, R., 2000. The LMP2A ITAM Is Essential for Providing B Cells with Development and Survival Signals In

Vivo. *Journal of Virology*, 74(19), 9115–9124.  
<https://doi.org/10.1128/JVI.74.19.9115-9124.2000>

Middeldorp, J. M., 2015. Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease. *Current Topics in Microbiology and Immunology*, 289–323. [https://doi.org/10.1007/978-3-319-22834-1\\_10](https://doi.org/10.1007/978-3-319-22834-1_10)

Middeldorp, J. M., Brink, A. A. T. P., Brule, A. J. C. V. D., Meijer, C. J. L. M., 2002. Pathogenic roles for Epstein-Barr virus (EBV) gene product in EBV-associated proliferative disorder. *Critical Reviews in Oncology/Hematology* 45 (2003) 1-36

Mohamed, G., Vrzalikova, K., Cader, F. Z., Vockerodt, M., Nagy, E., Flodr, P., Yap, L. F., Diepstra, A., Kluin, P. M., Rosati, S., and Murray, P., 2014. Epstein-Barr virus, the germinal centre and the development of Hodgkin's lymphoma. *Journal of General Virology* (2014), 95, 1861–1869. <https://doi.org/10.1099/vir.0.066712-0>

Motulsky, H., 2018. *Intuitive Biostatistics A Nonmathematical Guide to Statistical Thinking* fourth edition. Newyork: Oxford University Press

Murray, P. R., Rosenthal, K. S., Pfaller, M. A., 2015. *Medical Microbiology* 8th Edition. Philadelphia:Elsevier.

Ng, T. W., Choi, C. W., Lee, M. C. H., Law, L. Y., Yau, T. K., Lee, A. W. M., 2010. Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. *Familial Cancer* (2010) 9:221–228. <https://doi.org/10.1007/s10689-009-9296-y>

Ng, W. T., Lee, M. C. H., Hung, W. M., Choi, C. W., Lee, K. C., Chan, O. S. H., and Lee, A. W. M., 2011. Clinical Outcomes and Patterns of Failure After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology Biology Physics*, 79(2), 420–428. doi:10.1016/j.ijrobp.2009.11.024. <https://doi.org/10.1016/j.ijrobp.2009.11.024>

Niedobitek, G., 2000. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. *J Clin Pathol: Mol Pathol* 2000;53: p. 248–254.

Nielsen, N. H., Mikkelsen, F., and Hansen, J. P. H., 2009. NASOPHARYNGEAL CANCER IN GREENLAND. *Acta Pathologica Microbiologica Scandinavica Section A Pathology*, 85A(6), 850–858. <https://doi.org/10.1111/j.1699-0463.1977.tb03900.x>

Nowag, H., Guhl, B., Thriene, K., Romao, S., Ziegler, U., Dengjel, J., & Münz, C., 2014. Macroautophagy Proteins Assist Epstein Barr Virus Production

and Get Incorporated Into the Virus Particles. *EBioMedicine*, 1(2-3), 116–125. <https://dx.doi.org/10.1016%2Fj.ebiom.2014.11.007>

Paramita, D. K., 2010. Diagnosis and Protective Aspects of Humoral Immune Response to Epstein-Barr Virus Encoded Protein in Nasopharyngeal Carcinoma.

Paramita, D. K., Fachiroh, J., Artama, W. T., van Benthem, E., Haryana, S. M., and Middeldorp, J. M., 2007. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. *Journal of Medical Virology*, 79(11), 1710–1721. <https://doi.org/10.1002/jmv.20987>

Paramita, D. K., Fachiroh, J., Haryana, S. M., & Middeldorp, J. M., 2008. *Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. Journal of Clinical Virology*, 42(4), 343–352. doi:10.1016/j.jcv.2008.03.006

Paramita, D. K., Fachiroh, J., Haryana, S. M., and Middeldorp, J. M., 2009. Two-Step Epstein-Barr Virus Immunoglobulin A Enzyme-Linked Immunosorbent Assay System for Serological Screening and Confirmation of Nasopharyngeal Carcinoma. *Clinical and Vaccine Immunology*, 16(5), 706–711. <https://doi.org/10.1128/CVI.00425-08>

Payne, S. (2017). *Methods to Study Viruses. Viruses*, 37–52. doi:10.1016/b978-0-12-803109-4.00004-0

Pewsner, D., Battaglia, M., Minder, C., Marx, A., Bucher, H. C., Egger, M., 2004. Ruling a Diagnosis in or out with “SpIn” and “SnNOut”: a note of caution. *BMJ* Volume 329 24 July 2004.

Perhimpunan Dokter Spesialis Telinga Hidung Tenggorok Bedah Kepala Leher Indonesia (PERHATI-KL) & Perhimpunan, 2017. Panduan Praktik Klinis PP PERHATI-KL DI BIDANG TELINGA HIDUNG TENGGOROK-KEPALA LEHER Volume 2.

Pfister DG, Ang K-K, Brizel DM, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*. 2013; 11: 917-923.

Pfister, D. (2014). *Stanzbiopsie der Prostata. Aktuelle Urologie*, 45(04), 320–323. doi:10.1055/s-0034-1365874

Posthuma-Trumpie, G. A., Wichers, J. H., Koets, M., Berendsen, L. B. J. M., Amerongen, A. V., 2011. Amorphous carbon nanoparticles: a versatile label for rapid diagnostic (immuno)assays. *Analytical and Bioanalytical Chemistry* January 2012, Volume 402, Issue 2, pp 593–600

- Putera, I., Ramadhan, M. G., Anindya, S., Sutanto, N R., Kurniawan,A., Hosea, F. N., Safitri, E. D., 2015. Relationship Between Salted Fish Consumption and Nasopharyngeal Carcinoma: An Evidence-based Case Report. *Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine*
- Raab-Traub, N., 2002. Epstein-Barr virus in the pathogenesis of NPC. *CANCER BIOLOGY*, Vol. 12, 2002: pp. 431-441. <https://doi.org/10.1016/S1044579X0200086X>
- Rao, D., Gu, J., Meng, X., Zhang, Q., Fu, M., Liu, Y., Chen, F., Cao, S. M., Hong, M. H., Liu, Q., 2012. *An Efficacy Analysis for Nasopharyngeal Carcinoma Screening of Different Screening Intervals. Journal of International Medical Research*, 40(2), 525-536.doi:10.1177/147323001204000214
- Razek, A. A. K. A., and King, A., 2012. MRI and CT of Nasopharyngeal Carcinoma. *American Journal of Roentgenology*, 198(1), 11-18. <https://dx.doi.org/10.2214/AJR.11.6954>
- Sastroasmoro, S., Ismael, S., 2014. *Dasar-dasar Metodologi Penelitian Klinis Edisi ke-5*. Jakarta: Sagung Seto
- Shannon-Lowe, C., & Rowe, M., 2014. Epstein Barr virus entry; kissing and conjugation. *Current Opinion in Virology*, 4, 78-84. <https://doi.org/10.1016/j.coviro.2013.12.001>
- Simon, R., 2015, Sensitivity, Specificity, PPV, and NPV for Predictive Biomarkers. *JNCI J Natl Cancer Inst* (2015) 107(8): djv153. <https://doi.org/10.1093/jnci/djv153>
- Smith, N. A., Baresel, P. C., Jackson, C. L., Ogolla, S., Toko, E. N., Heit, S., Piriou, E., Sumba, O. P., Middeldorp, J. M., Colborn, K. L., Rochford, R., 2018. Differences in the Epstein-Barr virus gp350 IgA antibody response are associated with increased risk for co-infection with a second strain of EBV. *The Journal of Infectious Diseases*. <https://doi.org/10.1093/infdis/jiy601>
- Shah, K., and Maghsoudlou, P., 2016. Enzyme-linked immunosorbent assay (ELISA): the basics. *British Journal of Hospital Medicine*, 77(7), C98-C101. <https://doi.org/10.12968/hmed.2016.77.7.C98>
- Stoker, S. D., van Diessen, J. N. A., de Boer, J. P., Karakullukcu, B., Leemans, C. R., and Tan, I. B., 2013. Current Treatment Options for Local Residual Nasopharyngeal Carcinoma. *Current Treatment Options in Oncology*, 14(4), 475-491. <https://dx.doi.org/10.1007%2Fs11864-013-0261-5>
- Sun, X., Bristol, J. A., Iwahori, S., Hagemeyer, S. R., Meng, Q., Barlow, E. A., Fingerroth J. D., Tarakanova, V. L., Kalejta, R. F., Kenney, S. C.,

2013. Hsp90 Inhibitor 17-DMAG Decreases Expression of Conserved Herpesvirus Protein Kinases and Reduces Virus Production in Epstein-Barr Virus-Infected Cells. *Journal of Virology*, 87(18), 10126–10138. <https://doi.org/10.1128/jvi.01671-13>
- Swaminathan, S., and Kenney, S., 2008. The Epstein–Barr Virus Lytic Life Cycle. *DNA Tumor Viruses*, 285–315. [http://dx.doi.org/10.1007/978-0-387-68945-6\\_13](http://dx.doi.org/10.1007/978-0-387-68945-6_13)
- Tay, J. K., Chan, S. H., Lim, C. M., Siow, C. H., Goh, H. L., and Loh, K. S., 2016. The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma. *Otolaryngology-Head and Neck Surgery*, 155(2), 274–280. <https://doi.org/10.1177%2F0194599816641038>
- Tortora, G. J., Funke, B. R., Case, C. L., 2016. *Microbiology: An Introduction* 12<sup>th</sup> edition. Pearson
- Tosteson, A. N. A., Fryback, D. G., Hammond, C. S., Hanna, L. G., Grove, M. R., Brown, M., Wang, Q. F., Lindfors, K., Pisano, E. D., 2014. Consequences of False-Positive Screening Mammograms. *JAMA Intern Med.* 2014 June 1; 174(6): 954–961. <https://doi.org/10.1001/jamainternmed.2014.981>
- Tsao, S. W., Yip, Y. L., Tsang, C. M., Pang, P. S., Lau, V. M. Y., Zhang, G. T., 2014. Etiological factors of nasopharyngeal carcinoma. *Oral Oncology* 50 (2014), p. 330-338. <https://doi.org/10.1016/j.oraloncology.2014.02.006>
- Verkuijlen, S. A., Branislav, M., Scheepbouwer, C., Koppers-Lalic, D., 2018. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal- from head & neck cancer and asymptomatic EBV-infections. *International Journal of Cancer* · November 2018. <https://doi.org/10.1002/ijc.31967>
- Vistarop, A. G., Cohen, M., De Matteo, E., Preciado, M. V., and Chabay, P. A., 2016. Analysis of Epstein-Barr virus infection models in a series of pediatric carriers from a developing country. *Scientific Reports*, 6(1). <https://dx.doi.org/10.1038%2Fsrep23303>
- Vokes, E. E., Liebowitz, D. N., and Weichselbaum, R. R., 1997. Nasopharyngeal carcinoma. *The Lancet*, 350(9084), 1087–1091. [https://doi.org/10.1016/S0140-6736\(97\)07269-3](https://doi.org/10.1016/S0140-6736(97)07269-3)
- Wang, K., 2017. Nasopharyngeal Carcinoma Diagnostic Challenge in a Nonendemic Setting: Our Experience with 101 Patients. *The Permanente Journal*. <https://doi.org/10.7812/tpp/16-180>

- Wei, W. I., and Sham, J. S., 2005. Nasopharyngeal carcinoma. *The Lancet*, 365(9476), 2041–2054. [https://doi.org/10.1016/S0140-6736\(05\)66698-6](https://doi.org/10.1016/S0140-6736(05)66698-6)
- WHO, 2014. Nasopharyngeal Carcinoma Union for International Cancer Control 2014 Review of Cancer Medicine on the HO List of Essential Medicine.
- Wong, M. M. F., Lye, M. S., Cheng, H. M., Sam, C. K., 2005. Epstein-Barr Virus Serology in the Diagnosis of Nasopharyngeal Carcinoma. *ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY* (2005) 23: 65-67
- Xia, C., Zhu, K., Zheng, G. X., 2015. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis. *Int J Clin Exp Pathol* 2015;8(12):16104-16110.
- Xiao, W.W., Han, F., Lu, T.-X., Chen, C.-Y., Huang, Y., and Zhao, C., 2009. Treatment Outcomes After Radiotherapy Alone for Patients With Early-Stage Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology Biology Physics*, 74(4), 1070–1076. <https://doi.org/10.1016/j.ijrobp.2008.09.008>
- Yee, J., White, R. E., Anderton, E., and Allday, M. J., 2011. Latent Epstein-Barr Virus Can Inhibit Apoptosis in B Cells by Blocking the Induction of NOXA Expression. *PLoS ONE*, 6(12), e28506. <https://dx.doi.org/10.1371/journal.pone.0028506>
- Young, L. S., Dawson, C. W., 2014. Epstein-Barr virus and nasopharyngeal carcinoma. *Chin J Cancer*; 2014; Vol. 33 Issue 12. p. 581-590. <https://doi.org/10.5732/cjc.014.10197>
- Young, L. S., Dawson, C. W., Clark, D., Rupani, H., Busson, P., Tursz, T., Johnson, A., And Rickinson, A. B., 1998. Epstein-Barr Virus Gene Expression in Nasopharyngeal Carcinoma. *J. gen. Virol.* (1988), 69, 1051-1065. <https://doi.org/10.1099/0022-1317-69-5-1051>
- Zeng, M. S., and Zeng, Y. X., 2010. Pathogenesis and Etiology of Nasopharyngeal Carcinoma. *Nasopharyngeal Cancer*, 9–25. [http://dx.doi.org/10.1007/978-3-540-92810-2\\_2](http://dx.doi.org/10.1007/978-3-540-92810-2_2)